Executive Committee 2021 - 2022 |
CINP proudly presents the
2021 - 2022 Executive Committee. By clicking on the pictures you can
access the curriculum vitae of each Executive Committee member. CINP President - Joseph Zohar, IsraelProf. Zohar is the past-President of the European College of Neuropsychopharmacology (ECNP). He is also chair of the Israeli consortium on PTSD, chair of the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), a board member for the International Master in Affective Neuroscience, and a visiting Professor at the University of Maastricht in The Netherland. Prof. Zohar had authored over 350 papers, had written or took part in the writing of 16 books focusing on Resistant Depression, OCD, PTSD and Psychotropic. He was the founding associate editor of CNS Spectrums and of the World Journal of Biological Psychiatry. Prof. Zohar was advisor to DSM – IV and 5 in OCD and co-chair of the Workgroup preparing the research agenda on OCD for DSM-5. He has pioneered and is currently the Chair of an international collaboration (joint venture of ECNP, ACNP, CINP, AsCNP and IUPAR) on developing new nomenclature for CNS drugs; NbN - Neuroscience based Nomenclature. He is also the chair of the Expert Platform on Mental Health focus on Depression Prof. Zohar had been honored with several awards, including the Fogarty International Research Fellowship Award (1984), the A.E. Bennet Award for Clinical Research (1986 and 2002), ECNP Neuroscience Award for Clinical Research (1998), and the WFSBP Award for Excellence in Education (2001). Prof. Zohar has recently (2012) received funding (RO1) from National Institute of Mental Health (NIMH) to explore secondary prevention of PTSD and from NATO (2018) to develop a guideline on the treatment in the “Golden Hours” after a terror attack. He is also the Co-Chair of EU grant on Problematic Use of Internet PUI (2017). CINP Past President - Pierre Blier, CanadaDr Pierre Blier is a Full Professor for the Departments of Psychiatry and Cellular & Molecular Medicine in the Faculty of Medicine at the University of Ottawa in Ottawa, Ontario, Canada, and the Director of the Mood Disorders Research Unit at The Royal’s Institute of Mental Health Research. Dr Blier is on the editorial boards of several journals and is the co-editor in chief for the Journal of Psychopharmacolgy and field editor for translational medicine for the official journal of International College of Neuropsychopharmacology (CINP). In addition to his extensive list of publications and lectures presented worldwide, Dr. Blier has contributed to several treatment guidelines for psychiatric disorders. Dr Blier has a basic research laboratory investigating how psychotropic medications work in the brain, he carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.
Dr Blier received several awards for outstanding contributions to psychopharmacology including the Canada Research Chair in Psychopharmacology from the Government of Canada and is now a Fellow of the Royal Society of Canada (Life Sciences). He also serves on several committees, including the presidency elect of the CINP. CINP President Elect - Kazutaka Ikeda, Japan
As a research fellow at RIKEN Brain Science Institute
(1995-2000), he continued opioid and GIRK research and started studies
on the dopamine system. He was appointed Senior Research Fellow (2000),
Acting Chair (2002), and Chair (2003) in the Department of Molecular
Psychiatry, Tokyo Institute Psychiatry, and Leader of the Addiction
Substance Project (2011) and Chair of the Department of Psychiatry and
Behavioral Sciences at the Tokyo Metropolitan Institute of Medical
Science (2015). While at these institutions, he continued studies on
addiction, schizophrenia, analgesia, and neurodevelopmental disorders at
the molecular, genetic, animal-behavioral, and clinical levels. He has
approximately 300 publications on these topics in prominent scientific
journals. He was awarded the Distinguished International Scientist
Collaboration Program Award from the U.S. National Institute on Drug
Abuse in 2004, among several other awards. He is serving as an Academic
Editor of PLoS One, a Field Editor of Alcoholism: Clinical and Experimental Research,
and an Editorial Board Member of several other journals. He has been a
Fellow of CINP since 2010 and served as CINP Councillor (2016-2018). The Japanese Society of Neuropsychopharmacology (JSNP) has over 1300 members and is under the umbrella of CINP. He is currently President of JSNP (2016-2018). He is President-elect (2017-2018) of the Asian College of Neuropsychopharmacology (AsCNP), which has over 3000 members and is also under the umbrella of CINP. He is a member of the American College of Neuropsychopharmacolgy (since 2014). He is also a member of the Science Council of Japan (2014-2020). CINP Vice President - Dan Rujescu, Austria
CINP Vice President - Maria Oquendo, USA
Professor Oquendo is President of American College of Neuropsychopharmacology (ACNP), American Foundation for Suicide Prevention, past President of the American Psychiatric Association, CINP’s Vice-President Elect, and a National Academy of Medicine member, one of the highest honors in medicine. A recipient of multiple international awards, most recently, she received the Dolores Shockley Award (ACNP, 2018). CINP Secretary - Gabriella Gobbi, Canada![]() Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center. Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research. Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari, Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain. Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology. She has received several fellowships for more than $10M as a principal investigator. She has won many prizes including the Canadian College of Neuropsychopharmacology (CCNP) Young investigator Award in 2012, the Venezia Prize in 2015 and the Sam Lal prize from the Boeckh Foundation in 2017. She has served as reviewer/editor for many journals, international grant agencies in Europe and the USA and has been invited to speak at conferences around the world. CINP Treasurer - Ming-Chyi Huang, Taiwan
|